1. Home
  2. PRTA vs DIN Comparison

PRTA vs DIN Comparison

Compare PRTA & DIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

N/A

Current Price

$9.27

Market Cap

449.7M

Sector

Health Care

ML Signal

N/A

Logo Dine Brands Global Inc.

DIN

Dine Brands Global Inc.

N/A

Current Price

$29.54

Market Cap

425.3M

ML Signal

N/A

Company Overview

Basic Information
Metric
PRTA
DIN
Founded
2012
1958
Country
Ireland
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Restaurants
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
449.7M
425.3M
IPO Year
2013
1994

Fundamental Metrics

Financial Performance
Metric
PRTA
DIN
Price
$9.27
$29.54
Analyst Decision
Buy
Hold
Analyst Count
9
7
Target Price
$19.00
$29.00
AVG Volume (30 Days)
312.7K
199.8K
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
2.78%
EPS Growth
N/A
N/A
EPS
0.26
0.92
Revenue
$814,000.00
$879,300,000.00
Revenue This Year
$1,111.38
$3.61
Revenue Next Year
N/A
$0.64
P/E Ratio
$36.69
$33.54
Revenue Growth
N/A
8.25
52 Week Low
$7.73
$22.85
52 Week High
$11.80
$39.68

Technical Indicators

Market Signals
Indicator
PRTA
DIN
Relative Strength Index (RSI) 49.71 27.04
Support Level $9.05 $28.05
Resistance Level $9.36 $30.32
Average True Range (ATR) 0.35 1.20
MACD 0.01 -0.50
Stochastic Oscillator 44.40 6.18

Price Performance

Historical Comparison
PRTA
DIN

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

About DIN Dine Brands Global Inc.

Dine Brands Global Inc owns and franchises thousands of restaurants under the International House of Pancakes (IHOP), Applebee's Neighborhood Grill + Bar (Applebee's), and the Fuzzy's Taco Shop (Fuzzy's) names. The company conducts its business through three reportable segments: Franchise, Company-owned restaurants, and Rental. The majority of its revenue is generated from the Franchise segment, which consists of IHOP, Applebee's, and Fuzzy's franchise operations and generates revenue mainly from royalties and advertising fees from several IHOP, Applebee's, and Fuzzy's franchised restaurants, in addition to revenues from the sale of proprietary IHOP and Fuzzy's products to its franchisees. Geographically, the majority of the company's revenues is generated from its domestic market.

Share on Social Networks: